{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:05:41Z","timestamp":1789646741906,"version":"4.0.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH065"],"award-info":[{"award-number":["ZR2023MH065"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474268"],"award-info":[{"award-number":["82474268"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303700"],"award-info":[{"award-number":["82303700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.xcrm.2026.102633","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T15:45:26Z","timestamp":1771602326000},"page":"102633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dual PD-1\/IL-2R\u03b1 targeting restores CD8+ T cell fitness via STAT5\/CD47 axis in SMARCA4-deficient NSCLC"],"prefix":"10.1016","volume":"7","author":[{"given":"Xiaoling","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0658-4479","authenticated-orcid":false,"given":"Haiyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102633_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102633_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.xcrm.2026.102633_bib3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients With Advanced Non\u2012Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102633_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib7","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtho.2023.01.091","article-title":"Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC","volume":"18","author":"Alessi","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.667","article-title":"Hyper-progressive disease after immune checkpoint inhibitor in SMARCA4-deficient small-cell lung carcinoma","volume":"8","author":"Chiba","year":"2020","journal-title":"Respirol. Case Rep."},{"key":"10.1016\/j.xcrm.2026.102633_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102633_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14098","article-title":"SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers","volume":"8","author":"Tagal","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2026.102633_bib11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/carcin\/bgp035","article-title":"BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer","volume":"30","author":"Rodriguez-Nieto","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xcrm.2026.102633_bib12","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1158\/1078-0432.CCR-20-1825","article-title":"The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer","volume":"26","author":"Schoenfeld","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102633_bib13","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jtho.2020.03.030","article-title":"Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC","volume":"15","author":"Zhou","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.jtho.2020.01.002","article-title":"Clinicopathologic Characteristics of BRG1-Deficient NSCLC","volume":"15","author":"Dagogo-Jack","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216022","article-title":"SMARCA4: Current status and future perspectives in non-small-cell lung cancer","volume":"554","author":"Tian","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2026.102633_bib16","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2340154","article-title":"Redoxhigh phenotype mediated by KEAP1\/STK11\/SMARCA4\/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma","volume":"13","author":"Wei","year":"2024","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2026.102633_bib17","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jtho.2021.03.024","article-title":"SMARCA4 and Other SWItch\/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition","volume":"16","author":"Alessi","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2026.102633_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-immunol-042617-053352","article-title":"Signaling and Function of Interleukin-2 in T Lymphocytes","volume":"36","author":"Ross","year":"2018","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102633_bib19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.immunol.26.021607.090357","article-title":"The biology of interleukin-2","volume":"26","author":"Malek","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.xcrm.2026.102633_bib20","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1172\/JCI73639","article-title":"PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors","volume":"124","author":"Gros","year":"2014","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102633_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2026.102633_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stemlike CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102633_bib23","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153604","article-title":"Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity","volume":"132","author":"Ren","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102633_bib24","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.4049\/jimmunol.1800907","article-title":"IL-2\/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells","volume":"201","author":"Ward","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102633_bib25","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/s43018-023-00612-0","article-title":"IL-2Ra-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells","volume":"4","author":"Wu","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102633_bib26","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.xcrm.2026.102633_bib27","article-title":"Pan-Cancer Single-Nucleus Total RNA Sequencing Using snHH-Seq","volume":"11","author":"Chen","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2026.102633_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189187","article-title":"Intercellular adhesion molecule-1 (ICAM-1): From molecular functions to clinical applications in cancer investigation","volume":"1879","author":"Qian","year":"2024","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102633_bib29","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/0008-5472.CAN-24-2054","article-title":"Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102633_bib30","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1073\/pnas.160099797","article-title":"Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids","volume":"97","author":"Bianchi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102633_bib31","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/s41590-024-01804-1","article-title":"JAK-STAT signaling maintains homeostasis in T cells and macrophages","volume":"25","author":"Fortelny","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.xcrm.2026.102633_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity","volume":"10","author":"van Duijn","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2026.102633_bib33","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1084\/jem.193.7.855","article-title":"CD47-signal regulatory protein alpha (SIRPalpha) regulates Fcgamma and complement receptormediated phagocytosis","volume":"193","author":"Oldenborg","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.102633_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.152815","article-title":"Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC","volume":"7","author":"Chen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.xcrm.2026.102633_bib35","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.2000612","article-title":"Dynamic Roles for IL-2-STAT5 Signaling in Effector and Regulatory CD4+ T Cell Populations","volume":"205","author":"Jones","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.xcrm.2026.102633_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jri.2010.12.007","article-title":"Mechanisms involved in the expansion of Tregs during pregnancy: role of IL-2\/STAT5 signalling","volume":"88","author":"Fainboim","year":"2011","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.xcrm.2026.102633_bib37","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1182\/blood-2004-07-2823","article-title":"Adhesion of human T cells to antigen-presenting cells through SIRPbeta2-CD47 interaction costimulates T-cell proliferation","volume":"105","author":"Piccio","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2026.102633_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1349-7006.2006.00245.x","article-title":"CD47 regulation of epithelial cell spreading and migration, and its signal transduction","volume":"97","author":"Shinohara","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.xcrm.2026.102633_bib39","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy","volume":"75","author":"Hughes","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102633_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s43018-025-00909-2","article-title":"Linking macrophage metabolism to function in the tumor microenvironment","volume":"6","author":"Jin","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102633_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40364-021-00327-3","article-title":"Next frontier in tumor immunotherapy: macrophage-mediated immune evasion","volume":"9","author":"Qiu","year":"2021","journal-title":"Biomark. Res."},{"key":"10.1016\/j.xcrm.2026.102633_bib42","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.21037\/tlcr-2025-305","article-title":"STK11\/KEAP1 co-mutations in SMARCA4-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacy","volume":"14","author":"Dong","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102633_bib43","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/apm.13271","article-title":"STK11 mutation affects the killing effect of NK cells to promote the progression of lung adenocarcinoma","volume":"130","author":"Huang","year":"2022","journal-title":"APMIS"},{"key":"10.1016\/j.xcrm.2026.102633_bib44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature25986","article-title":"Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1","volume":"556","author":"Mills","year":"2018","journal-title":"Nature"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T16:20:42Z","timestamp":1783095642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2666379126000509"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102633","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual PD-1\/IL-2R\u03b1 targeting restores CD8+ T cell fitness via STAT5\/CD47 axis in SMARCA4-deficient NSCLC","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102633"}}